Table 1 Cell line-specific four-drug low-dose combinations and their efficacy in cell metabolic activity inhibition identified in the TGMO-based search.

From: Identification of low-dose multidrug combinations for sunitinib-naive and pre-treated renal cell carcinoma

Cells

A498

A498-ST

Caki-1

Caki-1-ST

786-O

786-O-ST

ECRF24

Drugs

MPC [µM]

Dose in ODC [µM]

Axitinib

0.02

–

–

–

–

–

–

0.02

AZD4547

0.4

0.4

0.4

0.4

0.4

0.4

0.4

–

AZD8055

0.03

0.02

0.01

0.03

0.03

–

0.03

–

Osimertinib

0.4

0.4

–

–

0.4

–

–

–

Pictilisib

2.0

1

0.5

0.75

2.0

2.0

2.0

0.5

Saracatinib

0.6

–

–

0.6

–

0.6

0.6

0.6

Selumetinib

0.6

–

0.6

–

–

0.6

–

0.6

Efficacy (% Ctrl)

66.3**

71.6**

70.0**

69.6**

67.8**

70.3**

53.5**

 ±SD

11

8

8

7

16

9

5

  1. **(p-value < 0.01) compared to the monotherapies and the DMSO control.
Back to article page